Amgen Inc. AMGN | NASDAQ

$296.47 $6.18 | 2.13%

After Hours
$293.75 -$2.72 | -0.92%

Company Overview:

Market Cap: $159.61B
PE Ratio: 24.26
52-Week Range: $253.30 - $339.17
Dividend Yield (FWD): 3.21% ($9.52)

10 Year AMGN Performance Metrics:

Total Return (with DRIP): 133.6% (8.85% CAGR)
Total Return (no DRIP): 112.7% (7.84% CAGR)
Share Price: 76.8% (5.86% CAGR)
Dividend Increase: 201.3% (11.64% CAGR)
AMGN 10-yr Total Return ($10K invested)
1Y 2Y 5Y 10Y All

AMGN Dividend Payments, Yield & Share Price charts

Dividend Payments & Yield
AMGN Dividend CAGR:1Y: 5.78%2Y: 5.71%5Y: 8.27%10Y: 11.66%
Share Price
AMGN Price CAGR:1Y: -8.89%2Y: 5.57%5Y: 4.34%10Y: 5.86%

Unlock All Reports & Research Dividend Stocks like a BOSS!

Monthly
$33/mo
7-days Free Trial
YMTracker + Earnings / Dividends / Estimate Reports for 1000s of Stocks
YieldMax PNL Tracker
✅ Visual Stock Research
✅ Stock Comparison Tools
✅ Dividend Stocks & ETFs
✅ Revenue & EPS Estimates
✅ Custom Dividend Reports
Start Free Trial
Yearly - 25% OFF
$297/yr
7-days Free Trial
Same features as Monthly
Get 3 months FREE!
YieldMax PNL Tracker
✅ Visual Stock Research
✅ Stock Comparison Tools
✅ Dividend Stocks & ETFs
✅ Revenue & EPS Estimates
✅ Custom Dividend Reports
Start Free Trial

AMGN Dividend Safety: Payout & Dividend to Free Cash Flow Ratios.

Dividend Payout Ratio - AMGN
7-Day FREE Trial Get Full Access Now!
Dividend to Free Cash Flow Ratio - AMGN
7-Day FREE Trial Get Full Access Now!

AMGN Earnings, Revenue, Cash & Debt, Shares Outstaning:

AMGN - Revenue
7-Day FREE Trial Get Full Access Now!
AMGN Revenue CAGR:1Y: 9.29%2Y: 14.55%5Y: 8.11%10Y: 5.49%
AMGN - Earnings Per Share (EPS)
7-Day FREE Trial Get Full Access Now!
AMGN EPS CAGR:1Y: 91.81%2Y: 1.49%5Y: -2.79%10Y: 2.10%
AMGN - Net Income
7-Day FREE Trial Get Full Access Now!
AMGN Net Income CAGR:1Y: 91.96%2Y: 1.90%5Y: -4.50%10Y: -1.42%
AMGN - EBITDA
7-Day FREE Trial Get Full Access Now!
AMGN EBITDA CAGR:1Y: 20.49%2Y: 23.64%5Y: 9.23%10Y: 4.75%
AMGN - Free Cash Flow
7-Day FREE Trial Get Full Access Now!
AMGN Free Cash Flow CAGR:1Y: -13.96%2Y: -29.44%5Y: -6.57%10Y: -3.33%
AMGN - Free Cash Flow / Share
7-Day FREE Trial Get Full Access Now!
AMGN Free Cash Flow / Share CAGR:1Y: -14.12%2Y: -29.63%5Y: -4.89%10Y: 0.07%
AMGN - Operating Income
7-Day FREE Trial Get Full Access Now!
AMGN Operating Income CAGR:1Y: 38.50%2Y: -0.75%5Y: 2.62%10Y: 2.45%
AMGN - Gross Profit
7-Day FREE Trial Get Full Access Now!
AMGN Gross Profit CAGR:1Y: 19.49%2Y: 9.09%5Y: 5.46%10Y: 3.70%
AMGN - Shares Outstanding
7-Day FREE Trial Get Full Access Now!
AMGN Shares Outstanding CAGR:1Y: 0.00%2Y: 0.37%5Y: -1.79%10Y: -3.44%
AMGN - Share Buybacks
7-Day FREE Trial Get Full Access Now!
AMGN Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: -100.00%10Y: -100.00%
AMGN - Stock-Based Comp
7-Day FREE Trial Get Full Access Now!
AMGN Stock-Based Comp CAGR:1Y: -100.00%2Y: 0.00%5Y: 0.00%10Y: -100.00%
AMGN - Expenses
7-Day FREE Trial Get Full Access Now!
AMGN Expenses CAGR:1Y: 55.04%2Y: 16.69%5Y: 18.49%10Y: 10.74%
AMGN - Revenue vs Net Income
7-Day FREE Trial Get Full Access Now!
AMGN - EPS vs FCF / Share
7-Day FREE Trial Get Full Access Now!
AMGN - EPS vs PE Ratio
7-Day FREE Trial Get Full Access Now!
AMGN - FCF vs FCF / Share
7-Day FREE Trial Get Full Access Now!
AMGN - FCF vs Stock Based Comp
7-Day FREE Trial Get Full Access Now!
AMGN - Cash & Debt
7-Day FREE Trial Get Full Access Now!
AMGN - Dividends
7-Day FREE Trial Get Full Access Now!
AMGN Dividend CAGR:1Y: 5.78%2Y: 5.71%5Y: 8.27%10Y: 11.66%
AMGN - Revenue by Segment
7-Day FREE Trial Get Full Access Now!
AMGN Revenue CAGR:1Y: 9.29%2Y: 14.55%5Y: 8.11%10Y: 5.49%
AMGN - Revenue by Region
7-Day FREE Trial Get Full Access Now!
AMGN Revenue CAGR:1Y: 9.29%2Y: 14.55%5Y: 8.11%10Y: 5.49%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

AMGN - REVENUE: Actual + Estimates
7-Day FREE Trial Get Full Access Now!
AMGN Actual Revenue CAGR:1Y: 9.29%2Y: 14.55%5Y: 8.11%10Y: 5.49%
AMGN - EPS: Actual + Estimates
7-Day FREE Trial Get Full Access Now!
AMGN Actual EPS CAGR:1Y: 91.81%2Y: 1.49%5Y: -2.79%10Y: 2.10%
AMGN - NET INCOME: Actual + Estimates
7-Day FREE Trial Get Full Access Now!
AMGN Actual Net Income CAGR:1Y: 91.96%2Y: 1.90%5Y: -4.50%10Y: -1.42%
AMGN - EBITDA: Actual + Estimates
7-Day FREE Trial Get Full Access Now!
AMGN Actual EBITDA CAGR:1Y: 20.49%2Y: 23.64%5Y: 9.23%10Y: 4.75%

Ratios, Profit Margins & Return on Capital:

AMGN - Net Profit Margin
7-Day FREE Trial Get Full Access Now!
AMGN Net Profit Margin CAGR:1Y: 75.70%2Y: -11.05%5Y: -11.67%10Y: -6.56%
AMGN - Gross Profit Margin
7-Day FREE Trial Get Full Access Now!
AMGN Gross Profit Margin CAGR:1Y: 9.33%2Y: -4.77%5Y: -2.45%10Y: -1.70%
AMGN - Price to Earnings
7-Day FREE Trial Get Full Access Now!
AMGN - Price To Sales Ratio
7-Day FREE Trial Get Full Access Now!
AMGN - Return on Capital Employed
7-Day FREE Trial Get Full Access Now!
AMGN - Return on Invested Capital
7-Day FREE Trial Get Full Access Now!

Compare stocks side-by-side
 

AMGN Dividends Info:

Annual Dividend: $9.52
Forward Yield: 3.21%
Ex-Dividend Date: 2025-08-22
Lifetime Dividends / Share: $77.27

AMGN Dividend History: Dates, Payments & Yield list

Below is a schedule of all AMGN dividend payments, ex-dates, share price on the day of the payment as well as TTM & forward yield

Ex-Date Payment Date Amount TTM Yield Forward Yield Price on Ex-Date
08/22/202509/12/2025$2.3803.23%0%$0.00
05/16/202506/06/2025$2.3803.4%3.28%$290.33
02/14/202503/07/2025$2.3803.14%2.93%$324.86
11/18/202412/09/2024$2.2503.23%3.24%$277.63
08/16/202409/06/2024$2.2502.76%2.81%$320.56
05/16/202406/07/2024$2.2502.78%2.95%$305.02
05/17/202406/07/2024$2.2500%2.95%$305.02
02/15/202403/07/2024$2.2502.99%3.3%$272.86
11/16/202312/08/2023$2.1303.17%3.17%$269.12
08/17/202309/08/2023$2.1303.16%3.28%$259.43
05/17/202306/08/2023$2.1303.62%3.86%$220.76
02/14/202303/08/2023$2.1303.3%3.73%$228.43
11/16/202212/08/2022$1.9402.73%2.72%$285.57
08/17/202209/08/2022$1.9403.03%3.16%$245.45
05/16/202206/08/2022$1.9403.03%3.16%$245.48
02/14/202203/08/2022$1.9403.22%3.36%$231.10
11/15/202112/08/2021$1.7603.39%3.3%$213.53
08/16/202109/08/2021$1.7602.98%3.19%$220.87
05/14/202106/08/2021$1.7602.67%2.97%$236.82
02/11/202103/08/2021$1.7602.79%3.09%$227.81
11/13/202012/08/2020$1.6002.7%2.8%$228.94
08/14/202009/08/2020$1.6002.61%2.65%$241.18
05/15/202006/08/2020$1.6002.54%2.83%$225.75
02/13/202003/06/2020$1.6002.67%3.04%$210.65
11/14/201912/06/2019$1.4502.65%2.48%$233.77
08/14/201909/06/2019$1.4502.85%2.79%$207.73
05/16/201906/07/2019$1.4503.26%3.3%$175.51
02/14/201903/08/2019$1.4502.9%3.21%$180.87
11/15/201812/07/2018$1.3202.74%2.76%$191.44
08/16/201809/07/2018$1.3202.6%2.69%$196.30
05/16/201806/08/2018$1.3202.84%2.86%$184.30
02/14/201803/08/2018$1.3202.66%2.82%$187.16
11/16/201712/08/2017$1.1502.69%2.62%$175.41
08/15/201709/08/2017$1.1502.62%2.55%$180.64
05/15/201706/08/2017$1.1502.69%2.83%$162.65
02/13/201703/08/2017$1.1502.48%2.59%$177.78
11/14/201612/08/2016$1.0002.73%2.85%$140.59
08/15/201609/08/2016$1.0002.17%2.34%$170.97
05/13/201606/08/2016$1.0002.35%2.53%$158.00
02/11/201603/08/2016$1.0002.38%2.77%$144.63
11/12/201512/07/2015$0.7902.09%2%$158.30
08/13/201509/08/2015$0.7901.77%2.04%$154.56
05/12/201506/05/2015$0.7901.77%2.01%$157.25
02/10/201503/06/2015$0.7901.72%2.04%$154.88
11/10/201412/05/2014$0.6101.5%1.44%$169.24
08/12/201409/05/2014$0.6101.82%1.77%$137.88
05/13/201406/06/2014$0.6101.95%2.07%$117.82
02/11/201403/07/2014$0.6101.67%2%$122.26
11/12/201312/06/2013$0.4701.67%1.65%$114.12
08/14/201309/06/2013$0.4701.66%1.69%$111.01
05/14/201306/07/2013$0.4701.54%1.9%$98.81
02/11/201303/07/2013$0.4701.83%2.02%$92.95
11/13/201212/07/2012$0.3601.68%1.63%$88.32
08/14/201209/07/2012$0.3601.63%1.72%$83.96
05/14/201206/07/2012$0.3601.82%2.08%$69.10
02/13/201203/07/2012$0.3601.35%2.15%$66.95
11/15/201112/08/2011$0.2800.99%1.92%$58.40
08/16/201109/08/2011$0.2800.55%2.02%$55.31

Projected Future Returns & Dividends for AMGN

Based on past 10-year performance, here are AMGN growth metrics:

Share price CAGR of +5.86%
Dividend CAGR of +11.66%

Using AMGN CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

AMGN (DRIP)AMGN - No DRIP
Current Price$296.47$296.47
Start Shares33.7333.73
Start Value$10,000$10,000
  
After 10 years:
Final Share Count50.8733.73
Dividends Payment$7.17$7.17
Annual Dividends$1,459$967
Yield on cost14.59%9.67%
Share Price$495.04$495.04
Total Dividends$6,946$5,543
Final Value$25,181$22,241

Estimated Future Value + Dividends - AMGN

NOTE: Above numbers are our estimate based on AMGN's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Monthly
$33/mo
7-days Free Trial
YMTracker + Earnings / Dividends / Estimate Reports for 1000s of Stocks
YieldMax PNL Tracker
✅ Visual Stock Research
✅ Stock Comparison Tools
✅ Dividend Stocks & ETFs
✅ Revenue & EPS Estimates
✅ Custom Dividend Reports
Start Free Trial
Yearly - 25% OFF
$297/yr
7-days Free Trial
Same features as Monthly
Get 3 months FREE!
YieldMax PNL Tracker
✅ Visual Stock Research
✅ Stock Comparison Tools
✅ Dividend Stocks & ETFs
✅ Revenue & EPS Estimates
✅ Custom Dividend Reports
Start Free Trial

Company Info

Amgen Inc. (AMGN) had its IPO on 1983-06-17, and is trader on NASDAQ stock exchange.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

AMGN website: https://www.amgen.com


Get Full Access to All Reports with DRIPCalc PRO

Monthly
$33/mo
7-days Free Trial
YMTracker + Earnings / Dividends / Estimate Reports for 1000s of Stocks
YieldMax PNL Tracker
✅ Visual Stock Research
✅ Stock Comparison Tools
✅ Dividend Stocks & ETFs
✅ Revenue & EPS Estimates
✅ Custom Dividend Reports
Start Free Trial
Yearly - 25% OFF
$297/yr
7-days Free Trial
Same features as Monthly
Get 3 months FREE!
YieldMax PNL Tracker
✅ Visual Stock Research
✅ Stock Comparison Tools
✅ Dividend Stocks & ETFs
✅ Revenue & EPS Estimates
✅ Custom Dividend Reports
Start Free Trial